Does Revvity’s Q2 Beat, Higher Guidance and China Exit Alter the Bull Case for RVTY?

Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to US$2.86 billion. Management attributed the earnings beat and raised outlook to improving pharma and biotech spending, strong Diagnostics growth, especially in reproductive health and...